PYRAZOLO[1,5-A][1,3,5]TRIAZINE-2-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

Title:

PYRAZOLO[1,5-A][1,3,5]TRIAZINE-2-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

Document Type and Number:

WIPO Patent Application WO/2019/154294

Kind Code:

A1

Abstract:

Disclosed are a pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative and the use of same as a therapeutic agent, in particular the use thereof as an A2a receptor antagonist and the use thereof in the preparation of drugs for treating conditions or diseases improved by the inhibition of A2a receptors.

More Like This:

WO/1999/040914	BICYCLIC PYRROLE DERIVATIVES AS MCP-1 INHIBITORS
JP5145218	Pyrazolo [3,4-D] azepine derivative as histamine H3 antagonist
WO/2007/066200	INHIBITORS OF CYSTEINE PROTEASES, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS

Inventors:

LU BIAO (CN)
GUI BIN (CN)
ZHANG JUNZHEN (CN)
HE FENG (CN)
TAO WEIKANG (CN)

Application Number:

PCT/CN2019/074324

Publication Date:

August 15, 2019

Filing Date:

February 01, 2019

Export Citation:

Click for automatic bibliography generation Help

Assignee:

JIANGSU HENGRUI MEDICINE CO (CN)
SHANGHAI HENGRUI PHARMACEUTICAL CO LTD (CN)

International Classes:

C07D487/04; A61K31/53; A61P1/16; A61P25/00; A61P35/00; C07D471/04

Domestic Patent References:

WO2000059907A2	2000-10-12
WO2004011464A2	2004-02-05
WO2017055305A1	2017-04-06
WO2007116106A1	2007-10-18
WO2009080197A1	2009-07-02
WO2009156737A1	2009-12-30
WO2011159302A1	2011-12-22
WO2011095625A1	2011-08-11
WO2014101373A1	2014-07-03
WO2015031221A1	2015-03-05
WO2013071697A1	2013-05-23
WO2005121111A1	2005-12-22

Foreign References:

CN1278819A	2001-01-03
CN201810118455A	2018-02-06
US20120172448A1	2012-07-05

Other References:

TRENDS IN NEUROSCI., vol. 29, no. 11, 2006, pages 647 - 654
EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 17, 2007, pages 979 - 991
CLIN. NEUROPHARMACOL., vol. 33, 2010, pages 55 - 60
J. NEUROSCI., vol. 30, no. 48, 2010, pages 16284 - 16292
PARKINSONISN RELAT. DISORD., vol. 16, no. 6, 2010, pages 423 - 426
MOV. DISORDERS, vol. 25, no. 2, 2010, pages S305
JENNER P., J NEUROL., vol. 24, no. 12, 2000, pages 1143 - 50
LOKSHIN, CANCER RES., vol. 66, no. 15, 1 August 2006 (2006-08-01), pages 7758 - 65
CHINESE PHARMACOLOGICAL BULLETIN, vol. 24, no. 5, 2008, pages 573 - 576
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol. 109, no. 3, 2011, pages 203 - 7
GESSI S ET AL., PHARMACOL. THER., vol. 117, no. 1, 2008, pages 123 - 140
JOURNAL OF CHEMICAL RESEARCH, vol. 40, no. 10, 2016, pages 594 - 596
JOURNAL OF ORGANIC CHEMISTRY, vol. 63, no. 12, 1998, pages 3884 - 3894
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, vol. 47, no. 24, 2008, pages 4512 - 4515
SYNTHESIS, vol. 7, 1981, pages 554 - 557
SYNTHETIC COMMUNICATIONS, vol. 38, no. 15, 2008, pages 2638 - 2645
JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 23, 2010, pages 8421 - 8439
TETRAHEDRON LETTERS, vol. 55, no. 41, 2014, pages 5591 - 5594
See also references of EP 3750891A4

Attorney, Agent or Firm:

SHANGHAI BESHINING LAW OFFICE (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: WASHING MACHINE

Next Patent: METHOD, DEVICE, AND SYSTEM FOR GUARANTEEING SERVICE LEVEL AGREEMENT OF APPLICATION